CatalystFDA/Bio

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in C

Phase 3 SANOVO trial met PFS endpoint for ORPATHYS plus TAGRISSO in MET-overexpressing EGFR-mutated lung cancer.

What changed

Phase 3 SANOVO trial met PFS endpoint for ORPATHYS plus TAGRISSO in MET-overexpressing EGFR-mutated lung cancer.

Why it matters

Phase 3 SANOVO trial met PFS endpoint for ORPATHYS plus TAGRISSO in MET-overexpressing EGFR-mutated lung cancer. — impact context not separately stored; see What changed.

Sources

eodhd